

## Communications to the Editor

### 3-Amino-4-hydroxybenzoic Acid: the Precursor of the C<sub>7</sub>N Unit in Asukamycin and Manumycin

Yiding Hu,<sup>†</sup> Chris R. Melville,<sup>‡</sup> Steven J. Gould,<sup>‡</sup> and Heinz G. Floss<sup>\*,†</sup>


Department of Chemistry, University of Washington  
Seattle, Washington 98195

Department of Chemistry, Oregon State University  
Corvallis, Oregon 97331

Received January 15, 1997

Antibiotics of the manumycin family, e.g., asukamycin (**1**)<sup>1,2</sup> from *Streptomyces nodosus* ssp. *asukaensis* and manumycin A (**2**)<sup>3–7</sup> from *Streptomyces parvulus* Tü 64, recently recognized as inhibitors of Ras protein farnesyltransferase<sup>8</sup> and of human interleukin-1 $\beta$  converting enzyme,<sup>9,10</sup> contain two short polyketide chains linked through a mC<sub>7</sub>N unit which serves as the starter unit for one of the polyketide chains. Unlike the mC<sub>7</sub>N units in ansamycin and mitomycin antibiotics, which arise from a parallel branch of the shikimate pathway,<sup>11</sup> the formation of the mC<sub>7</sub>N unit in the manumycin antibiotics is not related to the shikimate pathway. Feeding experiments established that the mC<sub>7</sub>N unit in both **1** and **2** arises from a 4-carbon dicarboxylic acid derived from succinic acid, giving rise to carbons 4–7, and a triose phosphate derived from glycerol, labeling carbons 1–3.<sup>12</sup> The triose phosphate is incorporated in such a way that the phosphorylated carbon gives rise to C-3, but with complete loss of deuterium attached to it.<sup>2</sup> The same labeling pattern was recently established<sup>13</sup> for 4-hydroxy-3-nitrosobenzamide (**3**), an iron-chelating metabolite isolated from *Streptomyces murayamaensis*.<sup>14</sup> Importantly, 3-amino-4-hydroxybenzoic acid (3,4-AHBA, **4**) had been established as a specific precursor of **3**,<sup>14</sup> leading to the suggestion<sup>13</sup> that **4** might also be a proximate precursor for the mC<sub>7</sub>N unit of the manumycin antibiotics. In this paper, we report experimental evidence in support of this hypothesis.

### Scheme 1



\* Author to whom correspondence should be addressed at Department of Chemistry, Box 351700, University of Washington, Seattle, WA 98195-1700.

<sup>†</sup> University of Washington.

<sup>‡</sup> Oregon State University.

(1) Kakinuma, K.; Ikekawa, N.; Nakagawa, A.; Ōmura, S. *J. Am. Chem. Soc.* **1979**, *101*, 3402.

(2) Cho, H.; Sattler, I.; Beale, J. M.; Zeeck, A.; Floss, H. G. *J. Org. Chem.* **1993**, *58*, 7925.

(3) Schröder, K.; Zeeck, A. *Tetrahedron Lett.* **1973**, *14*, 4995.

(4) Zeeck, A.; Schröder, K.; Frobels, K.; Grote, R.; Thiericke, R. *J. Antibiot.* **1987**, *40*, 1530.

(5) Zeeck, A.; Frobels, K.; Heusel, C.; Schröder, K.; Thiericke, R. *J. Antibiot.* **1987**, *40*, 1541.

(6) Thiericke, R.; Stellwaag, M.; Zeeck, A.; Snatzke, G. *J. Antibiot.* **1987**, *40*, 1549.

(7) Sattler, I.; Gröne, C.; Zeeck, A. *J. Org. Chem.* **1993**, *58*, 6583.

(8) Hara, M.; Akasaka, K.; Akimaya, S.; Okabe, M.; Nakano, H.; Gomez, R.; Wood, D.; Uh, M.; Tamanoi, F. *Proc. Nat. Acad. Sci. U.S.A.* **1993**, *90*, 2281.

(9) Uosaki, Y.; Agatsuma, T.; Tanaka, T.; Saitoh, Y. *J. Antibiot.* **1996**, *49*, 1079.

(10) Tanaka, T.; Tsukuda, E.; Uosaki, Y.; Matsuda, Y. *J. Antibiot.* **1996**, *49*, 1085.

(11) Kim, C.-G.; Kirschning, A.; Bergon, P.; Zhou, P.; Su, E.; Sauerbrey, B.; Ning, S.; Ahn, Y.; Breuer, M.; Leistner, E.; Floss, H. G. *J. Am. Chem. Soc.* **1996**, *118*, 7486 and references therein.

(12) Thiericke, R.; Zeeck, A.; Nakagawa, A.; Ōmura, S.; Herrold, R.; Wu, S. T. S.; Beale, J. M.; Floss, H. G. *J. Am. Chem. Soc.* **1990**, *112*, 3979.

(13) Gould, S. J.; Melville, C.; Cone, M. C. *J. Am. Chem. Soc.* **1996**, *118*, 9228.

(14) Cone, M. C.; Melville, C. R.; Carney, J. R.; Gore, M. P.; Gould, S. J. *Tetrahedron Lett.* **1995**, *51*, 3095.


In an initial experiment, 15 mg of [2-<sup>2</sup>H]-**4** ammonium salt (80 atom % <sup>2</sup>H) was fed to four 100 mL shake cultures of *S. nodosus* ssp. *asukaensis* ATTC 29757<sup>15</sup> at 24 h after inoculation. The cultures were harvested at 84 h and worked up as described,<sup>12</sup> except that HPLC (gradient of CH<sub>3</sub>OH/H<sub>2</sub>O) was substituted for the Sephadex LH-20 chromatography. <sup>2</sup>H NMR analysis of the resulting **1** (5 mg) showed a single signal at  $\delta = 7.36$  ppm corresponding to deuterium at C-3 of the mC<sub>7</sub>N unit of **1** [16.5 atom % <sup>2</sup>H enrichment, as determined by electrospray mass spectrometry select-ion monitoring (ES-MS SIM) method]. To confirm this result, [7-<sup>13</sup>C]-**4** was synthesized from 4-hydroxy-[7-<sup>13</sup>C]benzoic acid<sup>16</sup> by nitration followed by reduction of the nitro group with N<sub>2</sub>H<sub>4</sub>/Raney nickel. This material (10 mg, 99% <sup>13</sup>C) was fed to ten 100 mL cultures of *S. nodosus* ssp. *asukaensis* as described above. <sup>13</sup>C NMR analysis of the **1** produced (10 mg) in CDCl<sub>3</sub> gave a single enriched signal at 136.2 ppm, corresponding to C-7 of **1** (16.5% <sup>13</sup>C enrichment determined by ES-MS SIM).

The above results demonstrate unequivocally that 3,4-AHBA is a specific precursor of the mC<sub>7</sub>N moiety of **1**, providing the starter unit for the "southern" polyketide chain (Scheme 1). Its formation from a C<sub>4</sub> and a C<sub>3</sub> building block<sup>13</sup> must involve the complete loss of all deuterium from the carbon of the C<sub>3</sub> precursor which gives rise to C-2 of **4**. This follows from the fact that 1(*R*),2(*S*)- and 1(*S*),2(*S*)-[1-<sup>2</sup>H]<sub>1</sub>glycerol were incorporated into **1** with complete loss<sup>2</sup> of their deuterium, whereas [2-<sup>2</sup>H]-**4** retained its deuterium in the process. The further

(15) Seed cultures were grown in 500 mL Erlenmeyer flasks containing 100 mL of medium [20 g of glucose, 5 g of Bacto Peptone, 0.25 g of K<sub>2</sub>HPO<sub>4</sub>, 0.25 g of MgSO<sub>4</sub>, 50 mg of FeSO<sub>4</sub>·7H<sub>2</sub>O, 10 mg of MnCl<sub>2</sub>·4H<sub>2</sub>O, 5 mg each of (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O, CuSO<sub>4</sub>·5H<sub>2</sub>O, and ZnSO<sub>4</sub>·7H<sub>2</sub>O, deionized H<sub>2</sub>O (1 L)] for 3 days at 28 °C with rotary shaking at 300 rpm. One-tenth of a seed culture was used to inoculate each production flask containing 100 mL of the same medium; these were incubated in the same way.

(16) Cho, H.; Beale, J. M.; Graff, C.; Mocek, U.; Nakagawa, A.; Ōmura, S.; Floss, H. G. *J. Am. Chem. Soc.* **1993**, *115*, 12296.

## Scheme 2



conversion of the aromatic ring of **4** into the epoxyquinol structure of **1**, which probably occurs after polyketide synthesis, may plausibly involve the same dioxygenase mechanism<sup>17</sup> demonstrated for the oxidation of dihydrovitamin K<sup>18–20</sup> and the oxidation of dihydroxyacetanilide in the biosynthesis of antibiotics LL-C10037 and MPP3051<sup>21</sup> (Scheme 2). A necessary consequence of this mechanism is that the epoxide and the quinol oxygen in the product must be *syn* oriented. Compound **1** meets this condition,<sup>2</sup> as do the majority of the manumycins<sup>7,22</sup> and related compounds.<sup>9,23,24</sup> However, both

(17) Ham, S. W.; Dowd, P. *J. Am. Chem. Soc.* **1990**, *112*, 1660.

(18) Naganathan, S.; Hershline, R.; Ham, S. W.; Dowd, P. *J. Am. Chem. Soc.* **1994**, *116*, 9831.

(19) Dowd, P.; Hershline, R.; Ham, S. W.; Naganathan, S. *Science* **1995**, *269*, 1684 and references therein.

(20) Kuliopulos, A.; Hubbard, B. R.; Lam, Z.; Koski, I. J.; Furie, B.; Furie, B. C.; Walsh, C. T. *Biochemistry* **1992**, *31*, 7722.

(21) Gould, S. J.; Kirchmeier, M. J.; LaFever, R. E. *J. Am. Chem. Soc.* **1996**, *118*, 7663.

manumycin A and B, the major metabolites of *S. parvulus* Tü 64, carry the epoxide and quinol oxygens in an *anti* arrangement.<sup>6,7</sup> It was therefore of interest to check if **4** is also a precursor to these compounds.

[7-<sup>13</sup>C]3,4-AHBA (15 mg, 99% <sup>13</sup>C) was fed to ten 100 mL cultures of *S. parvulus* Tü 64, grown as described previously,<sup>12</sup> at 48 h after inoculation, and the cultures were harvested at 72 h. Standard workup<sup>12</sup> produced **2** (3 mg) which gave a single enriched <sup>13</sup>C NMR signal at 136.1 ppm corresponding to C-7. ES-MS analysis revealed 5.4% <sup>13</sup>C enrichment. A small amount of manumycin B was also isolated and showed 5.7% <sup>13</sup>C by ES-MS. Thus, **4** is a specific precursor of the mC<sub>7</sub>N unit of manumycin type antibiotics irrespective of the relative stereochemistry of the epoxyquinol moiety.

Three possible explanations can be invoked for this surprising observation: (i) the epoxyquinol moiety of manumycins A and B undergoes a stereochemical change after its formation, (ii) the stereochemical assignment of manumycins A and B is in error, or (iii) the dioxygenase mechanism of epoxyquinol formation does not apply to the manumycin antibiotics. We are presently attempting to distinguish between these possibilities.

**Acknowledgment.** This work was supported by NIH grants AI 20264 (H.G.F.) and GM 31715 (S.J.G.). We thank Professor Axel Zeeck, University of Göttingen, for the culture of *S. parvulus* Tü 64 and for generous exchange of information.

JA9701016

(22) Shu, Y.; Huang, S.; Wang, R. R.; Lam, K. S.; Klohr, S. E.; Volk, K. J.; Pirnik, D. M.; Wells, J. S. *J. Antibiot.* **1994**, *47*, 324.

(23) Grote, R.; Zeeck, A.; Beale, J. M. *J. Antibiot.* **1988**, *41*, 1186.

(24) Franco, C. M. M.; Maurya, R.; Vijayakumar, E. K. S.; Chatterjee, S.; Blumbach, J.; Ganguli, B. N. *J. Antibiot.* **1991**, *44*, 1289.